Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Filiberto Cedeno-Laurent, Elisha M. Singer, Maria Wysocka, Bernice M. Benoit, Carmela C. Vittorio, Ellen J. Kim, Gil Yosipovitch, Alain H. Rook

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalClinical Immunology
Volume158
Issue number1
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Cutaneous T-Cell Lymphoma
Interleukins
Pruritus
T-Lymphocytes
Therapeutics
Histone Deacetylase Inhibitors
Chemokine Receptors
Atopic Dermatitis
Cytokines

Keywords

  • CTCL
  • IL-31
  • Immunotherapy
  • Pruritus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Cedeno-Laurent, F., Singer, E. M., Wysocka, M., Benoit, B. M., Vittorio, C. C., Kim, E. J., ... Rook, A. H. (2015). Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clinical Immunology, 158(1), 1-7. https://doi.org/10.1016/j.clim.2015.02.014

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. / Cedeno-Laurent, Filiberto; Singer, Elisha M.; Wysocka, Maria; Benoit, Bernice M.; Vittorio, Carmela C.; Kim, Ellen J.; Yosipovitch, Gil; Rook, Alain H.

In: Clinical Immunology, Vol. 158, No. 1, 01.05.2015, p. 1-7.

Research output: Contribution to journalArticle

Cedeno-Laurent, F, Singer, EM, Wysocka, M, Benoit, BM, Vittorio, CC, Kim, EJ, Yosipovitch, G & Rook, AH 2015, 'Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities', Clinical Immunology, vol. 158, no. 1, pp. 1-7. https://doi.org/10.1016/j.clim.2015.02.014
Cedeno-Laurent, Filiberto ; Singer, Elisha M. ; Wysocka, Maria ; Benoit, Bernice M. ; Vittorio, Carmela C. ; Kim, Ellen J. ; Yosipovitch, Gil ; Rook, Alain H. / Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. In: Clinical Immunology. 2015 ; Vol. 158, No. 1. pp. 1-7.
@article{7df4d9783ed948d99261a60ffe6c713a,
title = "Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities",
abstract = "Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.",
keywords = "CTCL, IL-31, Immunotherapy, Pruritus",
author = "Filiberto Cedeno-Laurent and Singer, {Elisha M.} and Maria Wysocka and Benoit, {Bernice M.} and Vittorio, {Carmela C.} and Kim, {Ellen J.} and Gil Yosipovitch and Rook, {Alain H.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.clim.2015.02.014",
language = "English (US)",
volume = "158",
pages = "1--7",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

AU - Cedeno-Laurent, Filiberto

AU - Singer, Elisha M.

AU - Wysocka, Maria

AU - Benoit, Bernice M.

AU - Vittorio, Carmela C.

AU - Kim, Ellen J.

AU - Yosipovitch, Gil

AU - Rook, Alain H.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

AB - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

KW - CTCL

KW - IL-31

KW - Immunotherapy

KW - Pruritus

UR - http://www.scopus.com/inward/record.url?scp=84924985426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924985426&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2015.02.014

DO - 10.1016/j.clim.2015.02.014

M3 - Article

C2 - 25762519

AN - SCOPUS:84924985426

VL - 158

SP - 1

EP - 7

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -